| 1.55 -0.11 (-6.63%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.14  |
1-year : | 2.39 |
| Resists | First : | 1.83 |
Second : | 2.04 |
| Pivot price | 1.63 |
|||
| Supports | First : | 1.49 |
Second : | 1.23 |
| MAs | MA(5) : | 1.64 |
MA(20) : | 1.68 |
| MA(100) : | 1.68 |
MA(250) : | 1.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37.8 |
D(3) : | 43.5 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 2.85 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CNTB ] has closed above bottom band by 18.2%. Bollinger Bands are 58.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.67 - 1.68 | 1.68 - 1.69 |
| Low: | 1.52 - 1.53 | 1.53 - 1.54 |
| Close: | 1.53 - 1.55 | 1.55 - 1.57 |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - The Daily Jeffersonian
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - Canton Repository
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - gosanangelo.com
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - Zanesville Times Recorder
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - Ocala StarBanner
Mon, 03 Nov 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - The Sheboygan Press
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 1.434e+007 (%) |
| Held by Institutions | 40.5 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.906e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -27 % |
| Return on Assets (ttm) | 966.6 % |
| Return on Equity (ttm) | -30.6 % |
| Qtrly Rev. Growth | 1.97e+006 % |
| Gross Profit (p.s.) | 0.46 |
| Sales Per Share | 0.46 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 3.3 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 64300 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|